A Calgary-based company, Solvet, has received emergency use authorization from the U.S. Food and Drug Administration (FDA) to market its equine ivermectin product in the United States to combat screwworm. Solvet’s CEO, Lionel Gibbs, highlighted the unique characteristics of the aqueous-based solution, emphasizing its concentration and ease of administration.
Established in 2009 by two former University of Calgary professors, Solvet has evolved into one of Canada’s prominent veterinary pharmaceutical firms. Ivermectin, renowned for its effectiveness against various parasites, including screwworm, is being utilized to address the threat posed by this fly species in North America.
Screwworm infestations in livestock have historically resulted in significant economic losses in the U.S. and Mexico until successful eradication efforts were undertaken using the sterile insect technique. The recent reappearance of screwworm in North America has raised concerns, leading to regulatory actions such as temporary livestock import bans.
Solvet’s emergency use authorization for its ivermectin liquid in the U.S. specifically targets screwworm prevention in horses, highlighting the importance of timely administration for effective results. Experts like John Gilleard from the University of Calgary emphasize the critical role of this authorization in safeguarding animal welfare during screwworm outbreaks.
While the risk of screwworm in Canada remains low, authorities are closely monitoring the situation and collaborating with U.S. counterparts to adjust measures as needed. For Solvet, this authorization not only underscores its commitment to animal well-being but also presents a strategic opportunity for expansion and economic growth in Alberta.
